Peter Norman

1.7k total citations
100 papers, 1.3k citations indexed

About

Peter Norman is a scholar working on Molecular Biology, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Norman has authored 100 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 33 papers in Physiology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Norman's work include Asthma and respiratory diseases (31 papers), Cytokine Signaling Pathways and Interactions (13 papers) and Neuropeptides and Animal Physiology (11 papers). Peter Norman is often cited by papers focused on Asthma and respiratory diseases (31 papers), Cytokine Signaling Pathways and Interactions (13 papers) and Neuropeptides and Animal Physiology (11 papers). Peter Norman collaborates with scholars based in United Kingdom, Norway and United States. Peter Norman's co-authors include Phillip J. Gardiner, Nigel J. Cuthbert, Trevor S. Abram, M.G. McKenniff, Ian W. Rodger, Isabelle Gorenne, J.L. Ortiz, Carlos Labat, William A. Massey and L M Lichtenstein and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the New York Academy of Sciences and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Peter Norman

92 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Norman United Kingdom	18	582	436	301	267	202	100	1.3k
Peppi Prasit United States	21	234 0.4×	592 1.4×	120 0.4×	162 0.6×	126 0.6×	44	1.2k
JL Goldstein United States	8	394 0.7×	1.0k 2.4×	160 0.5×	112 0.4×	193 1.0×	10	2.4k
D.D. Soderman United States	12	211 0.4×	776 1.8×	169 0.6×	104 0.4×	122 0.6×	12	1.4k
Sonia Lamontagne Canada	19	302 0.5×	525 1.2×	87 0.3×	126 0.5×	191 0.9×	22	1.3k
K. V. Honn United States	23	94 0.2×	728 1.7×	90 0.3×	115 0.4×	338 1.7×	34	1.7k
Jonny Wijkander Sweden	22	251 0.4×	793 1.8×	228 0.8×	44 0.2×	119 0.6×	29	1.2k
Lisa M. Greene Ireland	21	132 0.2×	592 1.4×	52 0.2×	247 0.9×	259 1.3×	35	1.7k
Lori Capone Switzerland	9	128 0.2×	466 1.1×	399 1.3×	30 0.1×	179 0.9×	13	1.0k
Mariana S. De Lorenzo United States	19	154 0.3×	548 1.3×	255 0.8×	98 0.4×	329 1.6×	36	1.3k
Debra L. Burg United States	9	168 0.3×	364 0.8×	373 1.2×	27 0.1×	78 0.4×	11	872

Countries citing papers authored by Peter Norman

Since Specialization

Citations

This map shows the geographic impact of Peter Norman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Norman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Norman more than expected).

Fields of papers citing papers by Peter Norman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Norman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Norman. The network helps show where Peter Norman may publish in the future.

Co-authorship network of co-authors of Peter Norman

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Norman. A scholar is included among the top collaborators of Peter Norman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Norman. Peter Norman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Norman, Peter, et al.. (2025). METHODS IN DETERMINING NEW HIJRI MONTH: A THEMATIC REVIEW FROM ISLAMIC JURISPRUDENCE PERSPECTIVE. SHILAP Revista de lepidopterología. 13(1). 75–99.

Norman, Peter. (2015). Developments in inhaled combination therapies: patent activity 2013 – 2014. Expert Opinion on Therapeutic Patents. 25(11). 1–7. 2 indexed citations

Norman, Peter. (2015). Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs. 24(3). 383–392. 48 indexed citations

Norman, Peter. (2014). Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Patents. 24(6). 719–722. 5 indexed citations

Norman, Peter. (2014). Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and WO2013038390. Expert Opinion on Therapeutic Patents. 24(7). 829–837. 10 indexed citations

Norman, Peter. (2014). Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013. Expert Opinion on Therapeutic Patents. 24(5). 573–595. 26 indexed citations

Norman, Peter. (2014). Evaluation of WO2014075392 and WO2014075393, Merck’s first PI3Kδ inhibitor filings. Expert Opinion on Therapeutic Patents. 24(11). 1277–1282. 2 indexed citations

Norman, Peter. (2013). Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonists. Expert Opinion on Therapeutic Patents. 23(3). 383–388. 2 indexed citations

Norman, Peter. (2012). Evaluation of WO2012078210 – development process for the preparation of a DP2 receptor antagonist; Ironwood's first development DP2 antagonist. Expert Opinion on Therapeutic Patents. 22(10). 1257–1261. 1 indexed citations

10.

Norman, Peter. (2012). Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802. Expert Opinion on Therapeutic Patents. 22(2). 185–192. 3 indexed citations

11.

Norman, Peter. (2012). Evaluation of WO2012003387, Gilead's ASK1 inhibitors. Expert Opinion on Therapeutic Patents. 22(4). 455–459. 7 indexed citations

12.

Norman, Peter. (2011). Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333. Expert Opinion on Therapeutic Patents. 21(7). 1137–1142. 7 indexed citations

13.

Norman, Peter. (2011). A dual CCR2/CCR5 chemokine antagonist, BMS-813160?. Expert Opinion on Therapeutic Patents. 21(12). 1919–1924. 22 indexed citations

14.

Norman, Peter. (2011). A novel DP₂receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opinion on Therapeutic Patents. 21(12). 1931–1936. 6 indexed citations

15.

Norman, Peter. (2009). AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653. Expert Opinion on Therapeutic Patents. 19(11). 1629–1633. 12 indexed citations

16.

Norman, Peter. (2006). Long-acting muscarinic M₃receptor antagonists. Expert Opinion on Therapeutic Patents. 16(9). 1315–1320. 4 indexed citations

17.

Norman, Peter. (2001). Desloratadine: A preclinical and clinical overview. Drugs of today. 37(4). 215–215. 15 indexed citations

18.

Charlesworth, E.N., William A. Massey, A. Kagey-Sobotka, Peter Norman, & L M Lichtenstein. (1992). Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge.. Journal of Pharmacology and Experimental Therapeutics. 262(3). 964–970. 67 indexed citations

19.

Cuthbert, Nigel J., Phillip J. Gardiner, Trevor S. Abram, et al.. (1991). BAY u9773—an LTC₄ Antagonist in the Guinea Pig Trachea. Annals of the New York Academy of Sciences. 629(1). 402–404. 15 indexed citations

20.

Norman, Peter, et al.. (1987). The binding of [3H]leukotriene C4 to guinea-pig lung membranes. The lack of correlation of LTC4 functional activity with binding affinity. European Journal of Pharmacology. 143(3). 323–334. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact